NCT06428721 The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
| NCT ID | NCT06428721 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wright State University |
| Condition | Actinic Keratoses |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-03-20 |
| Primary Completion | 2031-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-03-20 with a primary completion date of 2031-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if the Fractionated Laser Resurfacing (FLR) procedure can protect one forearm/wrist from precancerous actinic keratosis (AKs) as well as prevent skin cancer in older subjects with active AKs. This study builds on a similar study ongoing at the Dayton Veterans Administration dermatology clinic. This study is also testing if a photograph of the skin can be used to predict where the AKs and an skin cancers will form.
Eligibility Criteria
Inclusion Criteria: * Adult Males and Females aged 60 and older * Have at least 5 AKs on each forearm/wrist, but no more than 10 to allow for easy monitoring * Skin type fair (Fitzpatrick I-II) * Females must be post-menopausal and not be on systemic hormone replacement therapy * Able to comprehend procedures and risks Exclusion Criteria: * More than 10 AKs on an extremity * AKs that are large (2-3+, hyperkeratotic grade 3 lesions) * AKs that are very thick (\>3 mm) * Medical history of diabetes * History of poor wound healing or scarring * Large tattoos that can interfere with study * Other serious health issues and other skin diseases that could interfere with the study * Recent (within 1 year) field therapies such as efudex cream or PDT to forearms/wrists. * Planning to leave region in next 5 years * Subjects with allergies to xylocaine will be excluded if they need this topical anesthetic.
Contact & Investigator
Jeffrey Travers, MD, PhD
PRINCIPAL INVESTIGATOR
Wright State University
Frequently Asked Questions
Who can join the NCT06428721 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Actinic Keratoses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06428721 currently recruiting?
Yes, NCT06428721 is actively recruiting participants. Contact the research team at pturesearch@wrightstatephysicians.org for enrollment information.
Where is the NCT06428721 trial being conducted?
This trial is being conducted at Fairborn, United States.
Who is sponsoring the NCT06428721 clinical trial?
NCT06428721 is sponsored by Wright State University. The principal investigator is Jeffrey Travers, MD, PhD at Wright State University. The trial plans to enroll 80 participants.